San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA 92120, USA.
Department of Psychiatry, University of California San Diego, San Diego, CA 92093, USA.
Viruses. 2023 Mar 3;15(3):674. doi: 10.3390/v15030674.
Methamphetamine and cannabis are two widely used substances among people living with HIV (PLWH). Whereas methamphetamine use has been found to worsen HIV-associated neurocognitive impairment, the effects of combined cannabis and methamphetamine use disorder on neurocognition in PLWH are not understood. In the present study, we aimed to determine the influence of these substance use disorders on neurocognition in PLWH and to explore if methamphetamine-cannabis effects interacted with HIV status.
After completing a comprehensive neurobehavioral assessment, PLWH ( = 472) were stratified by lifetime methamphetamine (M-/M+) and cannabis (C-/C+) DSM-IV abuse/dependence disorder into four groups: M-C- ( = 187), M-C+ ( = 68), M+C-, ( = 82), and M+C+ ( = 135). Group differences in global and domain neurocognitive performances and impairment were examined using multiple linear and logistic regression, respectively, while holding constant other covariates that were associated with study groups and/or cognition. Data from participants without HIV ( = 423) were added, and mixed-effect models were used to examine possible interactions between HIV and substance use disorders on neurocognition.
Compared with M+C+, M+C- performed worse on measures of executive functions, learning, memory, and working memory and were more likely to be classified as impaired in those domains. M-C- performed better than M+C+ on measures of learning and memory but worse than M-C+ on measures of executive functions, learning, memory, and working memory. Detectable plasma HIV RNA and nadir CD4 < 200 were associated with lower overall neurocognitive performance, and these effects were greater for M+C+ compared with M-C-.
In PLWH, lifetime methamphetamine use disorder and both current and legacy markers of HIV disease severity are associated with worse neurocognitive outcomes. There was no evidence of an HIV × M+ interaction across groups, but neurocognition was most impacted by HIV among those with polysubstance use disorder (M+C+). Better performance by C+ groups is consistent with findings from preclinical studies that cannabis use may protect against methamphetamine's deleterious effects.
冰毒和大麻是 HIV 感染者(PLWH)中两种广泛使用的物质。虽然已经发现冰毒使用会使 HIV 相关神经认知障碍恶化,但尚不清楚同时使用大麻和冰毒是否会对 PLWH 的神经认知产生影响。在本研究中,我们旨在确定这些物质使用障碍对 PLWH 神经认知的影响,并探讨是否存在冰毒-大麻与 HIV 状态的相互作用。
在完成全面的神经行为评估后,根据一生中是否存在 DSM-IV 冰毒(M-/M+)和大麻(C-/C+)滥用/依赖障碍,将 PLWH(=472)分为四组:M-C-(=187)、M-C+(=68)、M+C-(=82)和 M+C+(=135)。使用多元线性和逻辑回归分别检查各组在总体和领域神经认知表现和障碍方面的差异,同时控制与研究组和/或认知相关的其他协变量。添加无 HIV 的参与者数据(=423),并使用混合效应模型检查 HIV 和物质使用障碍对神经认知的可能相互作用。
与 M+C+相比,M+C-在执行功能、学习、记忆和工作记忆的测量上表现更差,并且更有可能被归类为这些领域的受损。M-C-在学习和记忆方面的表现优于 M+C+,但在执行功能、学习、记忆和工作记忆方面的表现劣于 M-C+。可检测的血浆 HIV RNA 和最低 CD4<200 与整体神经认知表现降低相关,并且对于 M+C+,这些影响大于 M-C-。
在 PLWH 中,终生使用冰毒障碍以及当前和遗留的 HIV 疾病严重程度标志物与更差的神经认知结果相关。各组之间没有 HIV×M+相互作用的证据,但对于多物质使用障碍(M+C+)患者,HIV 对神经认知的影响最大。C+组的更好表现与临床前研究一致,即大麻使用可能会保护免受冰毒的有害影响。